Publications by authors named "Marion Rabe"

Claim this Profile
C
Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment.
Marion Rabé, Lucie Fonteneau, Lisa Oliver, Alvaro Morales-Molina, Camille Jubelin

Front Cell Dev Biol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
Julien Fleurence, Meriem Bahri, Sophie Fougeray, Sébastien Faraj, Sarah Vermeulen

Int J Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma.
Marion Rabé, Solenne Dumont, Arturo Álvarez-Arenas, Hicham Janati, Juan Belmonte-Beitia

Cell Death Dis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Quentin Séry, Marion Rabé, Lisa Oliver, François M Vallette, Catherine Gratas

Biochem Biophys Res Commun· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity.
Kristell Oizel, Cynthia Chauvin, Lisa Oliver, Catherine Gratas, Fanny Geraldo, Marion Rabe

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Catherine Gratas, Quentin Séry, Marion Rabé, Lisa Oliver, François M Vallette

Oncotarget· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis